NCT05671432View on ClinicalTrials.gov

The Study of CM326 in Moderate-to-severe Atopic Dermatitis

PHASE2UnknownINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

December 27, 2022

Primary Completion Date

December 30, 2023

Study Completion Date

December 30, 2024

Conditions
Moderate-to-severe Atopic Dermatitis
Interventions
BIOLOGICAL

CM326

CM326 injection

OTHER

Placebo

Placebo

Trial Locations (1)

Unknown

RECRUITING

Peking University People's hospital, Beijing

Sponsors
All Listed Sponsors
lead

Keymed Biosciences Co.Ltd

INDUSTRY

NCT05671432 - The Study of CM326 in Moderate-to-severe Atopic Dermatitis | Biotech Hunter | Biotech Hunter